Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Sing2016 M2SR H3N2 Influenza Vaccine in Children
NCT04960397Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2021
- Primary completion
- Apr 2024
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Sing2016 M2SR H3N2 in influenza A (H3N2) (A(H3N2)) (4 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number and Percentage of Participants Experiencing a Solicited Reactogenicity Adverse Event, Number and Percentage of Participants Experiencing an Unsolicited Non-serious Adverse Event and 3 more. Started Sep 2021; status: terminated.
02
Drugs
Sing2016 M2SR H3N2
03
Conditions
influenza A (H3N2) (A(H3N2))
Beyond the preview
Go deeper on NCT04960397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04960397.